Bruce Brown, a nutrition industry executive who previously served as the end use market executive at Kerry, has joined Seraphina Therapeutics to lead the company’s growth strategy for its fatty acid ingredient, C15:0. This ingredient, the company reports, is the first essential fatty acid to be discovered in the past 90 years.

Prior to his role at Kerry, Brown was president and chief operating officer at Natreon, where he established a leadership position in patented bioactives and extracts for food, beverages, and dietary supplements.

Prior to this, Brown’s early career started in the public health sector, serving communities in West and East Africa for the Centers for Disease Control and Prevention (CDC) and the Carter Center.

In addition to his new role, Brown will continue to serve as chairman of the Council for Responsible Nutrition (CRN).

“I initially became excited about joining Seraphina Therapeutics because of the groundbreaking science supporting C15:0, and the opportunity to translate this science across numerous consumer markets, with the ultimate goal of positively impacting public health and quality of life,” said Brown. “As the first essential fatty acid to be discovered in over 90 years, C15:0 has the incredible power to prolong long-term health and strengthen against age-related decline. In my new role, I look forward to making C15:0 more accessible to all.”